POSC POSITRON CORP
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 844985 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-572.6%
Operating margin-2,287.6%
Net margin-2,307.6%
FCF margin—
EBITDA margin-2,278.9%
Returns
ROE-2,479.9%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets115.0%
Debt / equity—
Current ratio0.71x
Interest coverage-75.37x
Cash quality & payout
Operating cash flow / net income0.37x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $461,452 | $587,500 |
| Cost of revenue | $2.58M | $929,484 |
| Gross profit | -$2.11M | -$341,984 |
| SG&A expense | $8.38M | $1.86M |
| Operating income | -$10.50M | -$2.21M |
| Interest expense | $125,338 | $142,402 |
| Net income | -$10.60M | -$2.38M |
| EBITDA | -$10.47M | -$2.18M |
| EPS (basic) | -0.34 | -0.09 |
| EPS (diluted) | -0.34 | -0.09 |
| Weighted avg. shares (diluted) | 30.89M | 25.98M |
| Banking | ||
| Deposits | $375,000 | $375,000 |
| Balance sheet | ||
| Cash & equivalents | $2.52M | $69,791 |
| Receivables | $8,333 | $16,667 |
| Inventory | $680,000 | $1.26M |
| Current assets | $3.34M | $1.35M |
| PP&E, net | $105,752 | $34,103 |
| Total assets | $4.00M | $1.80M |
| Current liabilities | $2.40M | $2.43M |
| Long-term debt | $153,686 | $24,302 |
| Total debt | $153,686 | $24,302 |
| Total liabilities | $2.56M | $2.46M |
| Shareholders' equity | $1.44M | -$656,725 |
| Net debt | -$2.37M | -$45,489 |
| Shares outstanding | 32.80M | 27.31M |
| Cash flow statement | ||
| Operating cash flow | -$4.70M | -$1.73M |
| Investing cash flow | -$99,026 | — |
| Financing cash flow | $7.25M | $1.70M |
| Depreciation & amortization | $27,377 | $22,055 |
| Stock-based compensation | $4.98M | — |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.